Cook, Rebecca S.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 536

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A. (2012) · Cancer Research

PI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research

Cited by 368

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Balko, J. M., Cook, R. S., Vaught, D. B., Kuba, M. G., Miller, T. W., Bhola, N. E., Sanders, M. E., Granja-Ingram, N. M., Smith, J. J., Meszoely, I. M., et al. (2012) · Nature Medicine

Breast Cancer Treatment StudiesProtein Tyrosine Phosphatases

Cited by 262

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 203

Efferocytosis in the tumor microenvironment

Werfel, T. A., & Cook, R. S. (2018) · Seminars in Immunopathology

Phagocytosis and Immune RegulationCell death mechanisms and regulation

Cited by 156

HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation

Vaught, D. B., Stanford, J. C., Young, C., Hicks, D. J., Wheeler, F., Rinehart, C., Sánchez, V., Koland, J., Muller, W. J., Arteaga, C. L., et al. (2012) · Cancer Research

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 129

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene

PI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research

Cited by 102

Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy

Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 52

Efferocytosis Creates a Tumor Microenvironment Supportive of Tumor Survival and Metastasis

Vaught, D., Stanford, J. C., & Cook, R. S. (2015) · Cancer Cell & Microenvironment

Phagocytosis and Immune RegulationCell death mechanisms and regulation

Cited by 44

Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis

Colazo, J. M., Hoogenboezem, E. N., Keech, M. C., Francini, N., Shah, V., Yu, F., Lo, J. H., Sorets, A. G., McCune, J. T., Cho, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory)

RNA Interference and Gene DeliveryOsteoarthritis Treatment and Mechanisms

Cited by 11